The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland

European Journal of Health Economics

Volumn 6, Issue 3, 2005, Pages 267-273

  Tilson, Lesley ^a   Bennett, Kathleen ^b   Barry, Michael ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Drug expenditure; Generic substitution; Ireland; Medicines

Indexed keywords

GENERIC DRUG;

ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG PREFERENCE; DRUG SUBSTITUTION; HEALTH CARE COST; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE PRICING;

COST CONTROL; COSTS AND COST ANALYSIS; DRUG COSTS; DRUGS, GENERIC; HUMANS; IRELAND; STATE MEDICINE;

EID: 27844552254     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-005-0302-5     Document Type: Article

References (30)

1. General Medical Services Payments Board (2003) Report for the year ended 31st December 2003. Available at: http://www.gmspb.ie
2. General Medical Services Payments Board (2002) Report for the year ended 31st December 2002. Available at: http://www.gmspb.ie
3. Kanavos P (2002) Pharmaceutical pricing and reimbursement in Europe. In: Scrip reports regulatory affairs report series: PJB
4. Anonymous (2003) Swedish substitution leads to savings. Scrip 2929:3
5. Andersson K, Sonesson C, Petzold M, Carlsten A, Lonnroth K (2005) What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf (in press)
6. Barry M, Tilson L, Ryan M (2004) Pricing and reimbursement of drugs in Ireland. Eur J Health Econ 5:190-194
7. Anonymous (2004) British national formulary, 48th edn. Available at: http://www.bnf.org
8. European Parliament and Council Directive (2004) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use as amended by Directive 2002/98/EC, Directive 2004/24/EC and Directive 2004/27/EC
9. General Medical Services Payments Board (2001) Report for the year ended 31st December 2001. Available at: http://www.gmspb.ie
10. Anonymous (1996) Effective generic prescribing. MeReC Bull 7:37-40
11. Comptroller and Auditor General (1997) Prescribing practices and the development of general practitioner services. Stationary Office: Dublin
12. Walley T, Murphy M, Codd M, Johnston Z, Quirke T (2000) Effects of a monetary incentive on primary care prescribing in Ireland: changes in prescribing patterns in one health board 1990-1995. Pharmacoepidemiol Drug Saf 9:591-598
13. Pinto CG, Teixeira I (2002) Pricing and reimbursement of pharmaceutical in Portugal. Eur J Health Econ 3:267-270
14. G10 medicines report (2002) High level group on innovation and provision of medicines. Available at: http://pharmacos.eudra.org/F3/g10/g10home.htm
15. Garattini L, Tediosi F (2000) A comparative analysis of generics markets in five European countries. Health Policy 51:149-162
16. Delnoij D, Brenner G (2000) Importing budget systems from other countries: what can we learn from the German drug budget and the British GP fund-holding? Health Policy 52:157-169
17. Gaither CA, Duane MK, Ascione FJ, Welage LS (2001) Consumers' views on generic medications. J Am Pharm Assoc 41:729-736
18. Kasje WN, Timmer JW, Boendermaker PM, Haaijer-Ruskamp FM (2002) Dutch GPs' perceptions: the influence of out-of-pocket costs on prescribing. Soc Sci Med 55:1571-1578
19. Kanavos P, Mossialos E (1999) Outstanding regulatory aspects in the European pharmaceutical market. Pharmacoeconomics 15:519-533
20. Social Insurance Institution in Finland (2005) Generic substitution. Available at: http://193.209.217.5/in/internet/english.nsf/NET/220703130721MP? openDocument
21. McManus P, Birkett D, Dudley J, Stevens A (2001) Impact of the minimum pricing policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia. Pharmacoepidemiol Drug Saf 10:295-300
22. McGavock H (2001) Generic substitution - issues relating to the Australian experience. Pharmacoepidemiol Drug Saf 10:555-556
23. Schwermann T, Greiner W, Schulenburg J (2003) Using disease management and market reforms to address the adverse effects of drug budgets and price and reimbursement regulations in Germany. Value Health 6:520-530
24. Fricke FU, Rosenfeld S, Pirk O (2003) "Aut-idem"-saving drug costs does not mean savings in total health care costs. ISPOR Connections 9:6-8
25. Dietrich ES (2003) The aut-idem regulation in Germany: success or failure? National Association of Statutory Health Insurance Physicians. ISPOR 6th Annual European Congress: Barcelona
26. Orellana C (2002) Germany's generic-drug law promtps concern among doctors. Lancet 359:1498
27. Mott DA, Cline RR (2002) Exploring generic drug use behaviour: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care 40:662-674
28. Paraponaris A, Verger P, Desquins B et al. (2004) Delivering generics without regulatory incentives? Empirical evidence from French general practitioners about willingness to prescribe international non-proprietary names. Health Policy 70:23-32
29. Valles JA, Barreiro M, Cereza G et al. (2003) A prospective multicenter study of the effect of patient education on aceptability of generic prescribing in general practice. Health Policy 65:269-275
30. Hellstrom J, Rudholm N (2004) Side effects of generic competition? Eur J Health Econ 5:203-208